Replies to post #1682 on Vitro Diagnostics Inc (fka VODG)

[Potse]

db7...revenue disclosures.....

or perhaps it was not detailed on purpose as revs have been miniscule thus far

114% increase and 9.5 fold increase are attention getters

wouldn't have been too interesting if they said " from $15,000 to $32,000.... etc (i'm just making numbers up here for an example)

we'll see... appears most shares have effectively been soaked up at the .04-.05 level

That is the very first thought that entered my mind while reading the update. I didn't need to go back and check the filings since I already knew the company doesn't breakdown the product revenue. This type of shareholder update has the possibility of leaving a bad taste in existing/potential investors, so I think it would have been in the best interest of the company to simply provide all of the information.

The revenue numbers are still probably going to be relatively small, since the base numbers we are working from are small....

2011 full year: $23K
Q1 2012: $4.2K

But if it turns out that the main MSC-Gro product did account for a significant percentage in the above revenue periods, then this shareholder update would be reasonably encouraging to me. We would have the first tangible signs that the product is starting to gain some traction in the market. I don't know whether any of the revenue increases would be attributable to distribution channel filling, but if the Q1 2013 does turn out to be an improvement over Q4 2012 it might be an early sign of some revenue acceleration.